Moderna, Inc (MRNA) Sec Form 8K
Moderna, Inc (NASDAQ: MRNA) Sec Form 8K
50 articles, transcripts, and reports
Moderna, Inc (NASDAQ: MRNA) Sec Form 8K
Moderna Inc. (NASDAQ: MRNA) reported fourth-quarter 2025 revenue of $678 million, a 30% decrease from $966 million in the same...
Moderna, Inc (NASDAQ: MRNA) Q4 2025 Earnings Release
Moderna, Inc (NASDAQ: MRNA) Q4 2025 Earnings Conference
Moderna, Inc (NASDAQ: MRNA) Sec Form 8K
Moderna, Inc (NASDAQ: MRNA) FY 2026 Other Release
Moderna, Inc (NASDAQ: MRNA) Q2 2022 Earnings Call dated Aug. 03, 2022 Corporate Participants: Lavina Talukdar — Senior Vice President and Head of Investor Relations…
Moderna, Inc (NASDAQ: MRNA) Q2 2025 Earnings Call dated Aug. 01, 2025 Corporate Participants: Lavina Talukdar — Investor Relations Stephane Bancel — Chief Executive Officer…
Moderna, Inc (NASDAQ: MRNA) Q3 2025 Earnings Call dated Nov. 06, 2025 Corporate Participants: Lavina Talukdar — Head of Investor Relations Stephane Bancel — Chief…
Moderna, Inc. (NASDAQ: MRNA) reported a net loss for the first quarter of 2024 when the biotechnology company’s revenues declined sharply. Q1 loss was $1.18…